Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting

Read More

Ryvu Therapeutics Reports Third Quarter 2019 Financial Results

Read More

Ryvu Therapeutics to Present at BIO-Europe 2019

Read More

Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board

Read More

Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

Read More

Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland

Read More

Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company

Read More

Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Read More

Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed

Read More

Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer

Read More